In a landmark decision that addresses a long-standing void in pediatric medicine, the U.S. Food and Drug Administration (FDA) has officially approved the use of ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in newborns. The approval marks a critical expansion for the dispersible formulation, now indicated for infants weighing as little as 2 kg (approximately 4.4 pounds), effectively removing the previous age-based restrictions that had sidelined the most vulnerable patients from access to second-generation integrase inhibitors.
For clinicians and families, this regulatory milestone represents more than just a new prescription option; it is a vital step toward closing a persistent treatment gap. While pediatric HIV cases are relatively rare in the United States, the global burden remains significant, and the vulnerability of neonates necessitates specialized, highly effective, and tolerable pharmacological interventions.
The Evolution of Tivicay PD: A Chronology of Access
The journey of dolutegravir from an adult-focused therapy to a neonatal lifeline has been characterized by iterative clinical rigor and a focus on pediatric-specific formulations.
- August 2013: The FDA granted the initial approval for Tivicay (dolutegravir) tablets for the treatment of HIV-1 in adults and adolescents aged 12 years or older who weighed at least 40 kg (88.2 pounds).
- 2020: Recognizing the need for child-friendly administration, the FDA approved the dispersible tablet formulation, Tivicay PD. This version was initially indicated for patients at least four weeks old and weighing at least 3 kg (6.6 pounds).
- 2025 (CROI): Preliminary data from the NIH-funded IMPAACT 2023 study was presented at the Conference on Retroviruses and Opportunistic Infections (CROI), providing the clinical evidence needed to support dosing in the first weeks of life.
- August 2026: The FDA granted Priority Review and subsequent approval for the expanded indication, allowing for the use of Tivicay PD in infants weighing at least 2 kg from birth, removing the minimum-age barrier entirely.
Clinical Foundations: The IMPAACT 2023 Study
The approval of Tivicay PD for newborns is anchored in the robust data generated by the IMPAACT 2023 study, a multicenter Phase 1 trial that evaluated the safety, tolerability, and pharmacokinetics of dolutegravir in the earliest stages of life.
The trial enrolled 48 mother-infant pairs across clinical sites in South Africa, Thailand, and the United States. The research design focused on infants exposed to HIV-1 who weighed at least 2 kg. Participants received Tivicay PD starting at birth for a duration of up to six weeks, administered alongside standard-of-care antiretroviral regimens designed to prevent mother-to-child transmission.
Researchers maintained a rigorous 16-week follow-up period for all participants. The results were compelling: the drug levels observed in the neonates were consistent with the exposures associated with high efficacy in adult populations. Furthermore, the safety profile—a primary concern when introducing potent antiretrovirals to a developing system—mirrored the favorable outcomes observed in older pediatric and adult cohorts.
A specific cohort of 15 infants, who began treatment within their first five days of life, underwent a targeted dosing regimen of 5 mg every other day for the first two weeks, transitioning to daily dosing thereafter. This successful dosing strategy provided the necessary granularity for clinicians to confidently prescribe the medication to full-term infants in the neonatal period.
Official Perspectives: Addressing the Treatment Gap
The medical community has greeted the FDA’s decision with significant enthusiasm, citing the urgent need to address the high mortality rates associated with untreated neonatal HIV.
Diana F. Clarke, Pharm.D., a professor at the Boston University School of Medicine and the lead investigator for the IMPAACT 2023 study, emphasized the gravity of the situation in an official statement. "For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible," Clarke stated. She characterized the expansion as "an important advance for the care of newborns," underscoring that the lack of specialized neonatal therapeutics had previously hindered the ability of healthcare providers to initiate care at the optimal moment.
ViiV Healthcare has positioned this approval as part of its broader mission to eliminate pediatric HIV. By bringing the first second-generation integrase inhibitor to this specific age and weight demographic, ViiV provides a more robust, better-tolerated backbone for combination antiretroviral therapy (ART) in infants.
Implications for Global and Public Health
While the clinical impact on individual patients is the immediate focus, the broader public health implications of this approval are vast.
The Pediatric HIV Landscape
UNICEF has long documented the devastating trajectory of pediatric HIV, noting that approximately half of all babies living with the virus die before their second birthday if they do not receive timely, effective treatment. While the U.S. has achieved significant success in reducing the perinatal transmission rate to 1% or less, the availability of a highly effective treatment remains a cornerstone of maintaining these low numbers. In the U.S., fewer than 50 cases of perinatally acquired HIV have been recorded annually since 2018, yet the ability to manage these cases with modern, highly tolerable medications is essential for long-term health outcomes.
Economic and Portfolio Considerations for GSK/ViiV
From a commercial standpoint, the approval comes at a time of strategic transition for parent company GSK. While the standalone Tivicay brand has seen a plateau in global sales—reporting £1.323 billion in 2025, a slight decrease from the previous year—the company’s overall HIV portfolio remains a primary engine of growth.
The broader GSK HIV portfolio reached £7.687 billion in 2025, an 11% increase at constant exchange rates. This growth is largely driven by newer, long-acting products like Cabenuva and Apretude, as well as the oral regimen Dovato. By securing a pediatric indication for Tivicay PD, ViiV ensures the continued relevance of the dolutegravir molecule, reinforcing its role as a foundational component in pediatric care even as the adult market shifts toward newer delivery platforms.
Looking Toward the Future of Pediatric Antiretrovirals
The success of the IMPAACT 2023 study serves as a model for future pediatric drug development. By utilizing pharmacokinetic modeling alongside real-world, multicenter clinical data, researchers were able to navigate the complex regulatory hurdles of testing in newborns—a population often excluded from early clinical trials due to ethical and physiological considerations.
Moving forward, the medical community will continue to monitor the long-term outcomes of the infants treated under this new guidance. The shift toward integrating second-generation integrase inhibitors into neonatal care pathways is expected to reduce the incidence of drug resistance and improve adherence due to the simpler, more palatable nature of the dispersible formulation.
As the industry looks to further optimize HIV care, the focus will likely remain on developing even more accessible formulations, reducing the burden of daily dosing, and ensuring that low- and middle-income countries, where the burden of pediatric HIV is highest, can gain access to these life-saving advancements. For now, the FDA’s approval of Tivicay PD for newborns stands as a testament to what is possible when collaborative research, pediatric-focused study design, and regulatory prioritization align to serve the most vulnerable among us.
About the Author
